Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | CYP2A13 | Q16696 | 3/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737401 | 0.84 | DAO (0.48) | HTR7CYP2A13CTDSP1ALDH1A1MEN1 | |
| SCHEMBL739228 | 0.78 | HTR7 (0.73) | HTR7OPRM1ALDH1A1HPGDMEN1 | |
| Hydrochloric Acid SCHEMBL9725420 | 0.77 | HTR7 (0.71) | HTR7OPRM1ALDH1A1HPGDMEN1 | |
| SCHEMBL11199441 | 0.76 | PSMB8 (0.43) | HTR7ADRA1BOPRM1ALDH1A1HPGD | |
| SCHEMBL11193325 | 0.75 | ALDH1A1 (0.57) | HTR7ADRA1BOPRM1ALDH1A1HPGD | |
| SCHEMBL737292 | 0.75 | DAO (0.49) | HTR7CTDSP1ALDH1A1KDM4ECYP2C9 | |
| SCHEMBL7265868 | 0.74 | HTR7 (0.47) | HTR7CTDSP1ALDH1A1HPGDKDM4E | |
| SCHEMBL738090 | 0.74 | HTR7 (0.50) | HTR7OPRM1KDM4EMEN1KMT2A | |
| SCHEMBL11196807 | 0.73 | P2RX7 (0.71) | HTR7ADRA1BOPRM1MEN1CYP2C9 | |
| Hydrochloric Acid SCHEMBL9725415 | 0.73 | HTR7 (0.49) | HTR7OPRM1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138177-B2 | Benzimidazolone derivatives as CB2 receptor ligands | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-1861377-B1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | PFIZER (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | disclosed |
| EP-2114897-A2 | BENZIMIDAZOLONE DERIVATIVES | Pfizer Products Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | ANDO KAZUO | 2009-07-16 | — | — | US | disclosed |
| WO-2008032164-A2 | BENZIMIDAZOLONE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1861377-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | Pfizer, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097808-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | PFIZER JAPAN INC. (JP) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | TRPV1, CNR1, CNR2 | HTR7 209/4885CYP2A13 1986/4885ADRA1B 62/4885 |
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | TRPV1, CNR1, CNR2 | HTR7 335/4885CYP2A13 1320/4885ADRA1B 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.